HANGZHOU, China, March 17, 2025 /PRNewswire/ -- Chance Pharmaceuticals ("Chance Pharma ... today announced the successful completion of a new round of financing. Heda Health Fund and Qihang ...

Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Ascendis Pharma (ASND – Research Report) today and set a price target of $180.00. The company’s shares closed last Friday at ...

2025 Healthcare & Pharmaceuticalscategory Big pharma fears best-selling drugs in crosshairs of US-EU tariff spat March 18, 2025 Healthcare & Pharmaceuticalscategory Measles cases in Texas, New ...

In a report released today, Shane Storey from Wilsons maintained a Buy rating on Telix Pharmaceuticals Ltd. (TLPPF – Research Report), with a price target of A$35.00. The company’s shares ...

Police are investigating a possible arson attempt at the New Jersey home of a Bayer executive amid growing fears for the safety of pharma bigwigs following the assignation of UnitedHealthcare CEO ...

Each golden MLB logo patch will be removed from the jersey and wholly inserted into Topps cards.The resulting insert cards will be known as Gold Logoman cards. Fanatics, which acquired Topps in ...

To help organisations navigate this new terrain, Culjat provided advice for stakeholders on both sides. For software developers, he recommended identifying unmet needs within the pharma pipeline ...

Eton Pharmaceuticals, Inc. (NASDAQ ... expects to submit a New Drug Application (NDA) to the FDA in April 2025. Approval of ET-600 would mark the introduction of the only FDA-approved oral liquid ...

SAN DIEGO - Acadia Pharmaceuticals Inc. (NASDAQ ... has granted inducement awards to thirteen new employees as part of its 2024 Inducement Plan, the company reported Monday.

Bank of New York Mellon Corp cut its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 5.3% during the fourth quarter, HoldingsChannel reports. The firm owned 409,750 shares ...

Examples include Kite Pharma, formed from the foundational work ... cell and gene therapy has required the industry to establish new and distinct capabilities, such as optimal process development ...

Eton Pharmaceuticals, Inc. (NASDAQ ... rare diseases and generated $34.68 million in revenue over the last twelve months, expects to submit a New Drug Application (NDA) to the FDA in April 2025.